# A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

> **NCT05826574** · PHASE1 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Brensocatib
- **DRUG:** Rifampin
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT05826574
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-10
- **Primary completion:** 2023-07-16
- **Final completion:** 2023-07-16
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05826574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05826574, "A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05826574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*